The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial
Abstract
BACKGROUND: Fixed-dose mycophenolate mofetil (MMF) reduces the incidence of acute rejection after solid organ transplantation. The Fixed-Dose Concentration Controlled trial assessed the feasibility and potential benefit of therapeutic drug monitoring in patients receiving MMF after de novo renal transplant. METHODS: Patients were randomized to a concentration-controlled (n=452; target exposure 45 mg hr/L) or a fixed-dose (n=449) MMF-containing regimen. The primary endpoint was treatment failure (a composite of biopsy-proven acute rejection [BPAR], graft loss, death, or MMF discontinuation) by 12 months posttransplantation. RESULTS: Mycophenolic acid (MPA) exposures for both groups were similar at most time points and were below 30 mg hr/L in 37.3% of patients at day 3. There was no difference in the incidence of treatment failure (25.6% vs. 25.7%, P=0.81) or BPAR (14.9% vs. 15.5%, P>0.05) between the concentration-controlled and the fixed-dose groups, respectively. We did find a significant relationship between MPA-area under the concentration-time curve on day 3 and the incidence of BPAR in the first month (P=0.009) or in the first year posttransplantation (P=0.006). For later time points (day 10, month 1) there was no significant relationship between area under the concentration-time curve and BPAR (0.2572 and 0.5588, respectively). CONCLUSIONS: There was no difference in the incidence of treatment failure between the concentration-controlled and the fixed-dose groups. The applied protocol of MMF dose adjustments based on target MPA exposure was not successful, partly because physicians seemed reluctant to implement substantial dose changes. Current initial MMF doses underexpose more than 35% of patients early after transplantation, increasing the risk for BPAR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Banff 97 working classification of renal allograft pathology
Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00299.x · Cited by 3,033
Meur, Y. L., Büchler, M., Thierry, A., Caillard, S., Villemain, F., Lavaud, S., Étienne, I., Westeel, P. F., de Ligny, B. H., Rostaing, L. P. E., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01983.x · Cited by 416
The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation*
Hale, M. D., Nicholls, A. J., Bullingham, R. E. S., Hené, R., Hoitsma, A., Squifflet, J.-P., Weimar, W., Vanrenterghem, Y., Van de Woude, F. J., & Verpooten, G. A. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90058-3 · Cited by 399
Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation
van Gelder, T., Meur, Y. L., Shaw, L. M., Oellerich, M., DeNofrio, D., Holt, C., Holt, D. W., Kaplan, B., Kuypers, D., Meiser, B., et al. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000199358.80013.bd · Cited by 331
Self-citationWeber, L. T., Shipkova, M., Armstrong, V. W., Wagner, N., Schütz, E., Mehls, O., Zimmerhackl, L. B., Oellerich, M., & Tönshoff, B. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v133759 · Cited by 289
Self-citationOellerich, M., Shipkova, M., Schütz, E., Wieland, E., Weber, L., Tönshoff, B., & Armstrong, V. W. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200002000-00004 · Cited by 187
Self-citationLimited Sampling Strategy for Mycophenolic Acid Area Under the Curve
Filler, G., & Mai, I. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200004000-00005 · Cited by 124
Weber, L. T., Hoecker, B., Armstrong, V. W., Oellerich, M., & Tönshoff, B. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000246766.12872.12 · Cited by 56
Self-citationMonitoring Immunosuppressive Drugs: Has It a Future?
Holt, D. W., & Johnston, A. E. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200406000-00003 · Cited by 8
Self-citation
Cited by
Wallemacq, P., Armstrong, V. W., Brunet, M., Haufroid, V., Holt, D. W., Johnston, A., Kuypers, D., Meur, Y. L., Marquet, P., Oellerich, M., et al. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318198d092 · Cited by 468
Self-citationKidney Transplantation in Children
Dharnidharka, V. R., Fiorina, P., & Harmon, W. E. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1314376 · Cited by 265
Adherence profiles in kidney transplant patients: Causes and consequences
Villeneuve, C., Rousseau, A., Rerolle, J.-P., Couzi, L., Kamar, N., Essig, M., Etienne, I., Westeel, P.-F., Büchler, M., Esposito, L., et al. (2020) · Patient Education and Counseling · doi:10.1016/j.pec.2019.08.002 · Cited by 53
Metadata
- Authors
- van Gelder, T., Silva, H. T., de Fijter, J. W., Budde, K., Kuypers, D., Tyden, G., Lohmus, A., Sommerer, C., Hartmann, A., Le Meur, Y., Oellerich, M., Holt, D. W., Tönshoff, B., Keown, P., Campbell, S., & Mamelok, R. D.
- Venue
- Transplantation
- Published
- 2008-10-27
- Volume
- 86
- Issue
- 8
- Pages
- 1043-1051
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1987999831
- Cited by
- 284
- References
- 9
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. https://app.cochat.ai/papers/10.1097/tp.0b013e318186f98a
- The paper
- van Gelder, T., Silva, H. T., de Fijter, J. W., Budde, K., Kuypers, D., Tyden, G., Lohmus, A., Sommerer, C., Hartmann, A., Le Meur, Y., Oellerich, M., Holt, D. W., Tönshoff, B., Keown, P., Campbell, S., & Mamelok, R. D. (2008). Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. Transplantation. https://doi.org/10.1097/tp.0b013e318186f98a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.